ASP IsotopesASPI
ASPI
About: ASP Isotopes Inc is a pre-commercial stage materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
Employees: 136
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 3 (+2) [Q1 2025]
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
44% more call options, than puts
Call options by funds: $7.7M | Put options by funds: $5.36M
3% more funds holding
Funds holding: 92 [Q4 2024] → 95 (+3) [Q1 2025]
4% more capital invested
Capital invested by funds: $147M [Q4 2024] → $152M (+$5.27M) [Q1 2025]
0.03% more ownership
Funds ownership: 45.36% [Q4 2024] → 45.39% (+0.03%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$11
17%
upside
Avg. target
$11
17%
upside
High target
$11
17%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity George Gianarikas | 17%upside $11 | Buy Maintained | 21 May 2025 |
Financial journalist opinion
Based on 4 articles about ASPI published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates (AICsTM) For Cancer Treatment
- IsoBio, Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICs TM ), targeting both derisked and novel tumor antigens for patients in need of new cancer therapies.
Neutral
GlobeNewsWire
5 days ago
Competition Commission of South Africa Approves the Offer by ASP Isotopes Inc. for Renergen Limited
WASHINGTON, D.C., July 25, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that the Company's proposed offer to acquire all of the issued ordinary shares of JSE-listed Renergen Limited (“Renergen”) has been approved as of July 23, 2025, by the Competition Commission of South Africa, subject to certain conditions, which are acceptable to the Company.
Neutral
GlobeNewsWire
1 week ago
ASP Isotopes Inc. Announces Pricing of $60 Million Underwritten Registered Direct Offering of Common Stock
WASHINGTON, July 23, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), today announced the pricing of an underwritten registered direct offering of 7,500,000 shares of its common stock at a price of $8.00 per share to a single fundamental institutional investor. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $60.0 million. The offering is expected to close on or about July 25, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
2 weeks ago
Shareholders of Renergen Limited Approve Proposed Acquisition by ASP Isotopes Inc.
WASHINGTON, July 11, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that at a general meeting of shareholders of Renergen Limited (“Renergen”) held on July 10, 2025, Renergen shareholders voted overwhelmingly in favor of the acquisition of Renergen by ASP Isotopes through a scheme of arrangement (the “Scheme”) in accordance with Sections 114 and 115 of the South African Companies Act, No. 71 of 2008. The Scheme received support from 99.80% of voting shareholders.
Neutral
GlobeNewsWire
1 month ago
Renergen's Phase 2 EPC Contractor Awarded Preferred Bidder Status
JOHANNESBURG, June 18, 2025 (GLOBE NEWSWIRE) -- Renergen is pleased to announce that preferred bidder status has been awarded to He4u consortium for the design, procurement, delivery, construction and commissioning for phase 2 of the Tetra4 LNG and helium liquefaction project, comprising of, Chart Industries Inc. (NYSE: GTLS), Wilson Bayly Holmes - Ovcon Ltd (JSE: WBO), and Aurex Constructors. The appointment of an acceptable EPC contractor in Phase 2 was one of the two remaining conditions for the DFC Phase 2 loan.
Neutral
Accesswire
1 month ago
ASP Isotopes Inc. (ASPI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ASP Isotopes Inc. ("ASP Isotopes" or "the Company") (NASDAQ:ASPI). Investors who purchased ASP Isotopes securities prior to October 30, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ASPI.
Neutral
GlobeNewsWire
1 month ago
ASP Isotopes Inc. Enhances the Quantum Leap Energy LLC (QLE) Executive Leadership Team with the Appointment of Ryno Pretorius as Chief Executive Officer of QLE
WASHINGTON , June 11, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Dr. Ryno Pretorius, PhD as Chief Executive Officer of Quantum Leap Energy LLC (QLE), the Company's subsidiary that is pursuing an initiative to develop and commercialize advanced nuclear fuels, such as High Assay Low-Enriched Uranium (HALEU) and Lithium-6. Dr. Pretorius has previously served as a consultant to both ASP Isotopes and QLE.
Neutral
Accesswire
1 month ago
Bronstein, Gewirtz & Grossman, LLC Encourages ASP Isotopes Inc. (ASPI) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ASP Isotopes Inc. ("ASP Isotopes" or "the Company") (NASDAQ:ASPI). Investors who purchased ASP Isotopes securities prior to October 30, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ASPI.
Neutral
Accesswire
1 month ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating ASP Isotopes Inc. (ASPI) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ASP Isotopes Inc. ("ASP Isotopes" or "the Company") (NASDAQ:ASPI). Investors who purchased ASP Isotopes securities prior to October 30, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ASPI.
Neutral
Accesswire
1 month ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ASP Isotopes Inc. (ASPI) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ASP Isotopes Inc. ("ASP Isotopes" or "the Company") (NASDAQ:ASPI). Investors who purchased ASP Isotopes securities prior to October 30, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ASPI.
Charts implemented using Lightweight Charts™